On June 18 Health Minister Roberto
Speranza visited IRMB, the pharmaceutical research group that
controls Advent, a vaccines division that, together with Oxford
University's Jenner Institute, has developed and is producing
doses for the clinical trials on the Anticovid19 candidate
vaccine that are currently taking place.
The AstraZeneca multinational has signed protocols for the
production and distribution of this candidate vaccine with
several countries all over the world.
"Today I met the management and the female and male researchers
of IRMB, the Italian company that is working in collaboration
with the University of Oxford on the testing of the vaccine
against COVID-19," explained the minister, who visited the
Pomezia facility together with Nicola Magrini, the director
general of Italian medicines agency AIFA.
"Only a safe, effective vaccine can take us out of the
emergency.
"That's why Italy's role in the European initiative signed a few
days ago is important.
"We are proud of our scientists and of the excellence of Italian
research"..
ALL RIGHTS RESERVED © Copyright ANSA
